OR SB289

Changes the frequency of prescription drug reporting from the Department of Consumer and Business Services to the Prescription Drug Affordability Board from quarterly to annually

Requires the Prescription Drug Affordability Board's annual report to the legislature to include the status of the generic drug market alongside price trends, reviewed drugs, and recommendations

Removes the requirement for the Board to conduct an independent annual study of the U.S. generic drug market and eliminates the separate June 1 reporting deadline for that study

Streamlines generic drug market monitoring by incorporating key metrics (year-to-year prices, insurance premium impacts, cost-sharing changes, shortage potential, Medicaid spending effects) into existing reporting requirements